

# Approximating reaching zero-dose children with standardized country-level outreach vaccine delivery unit cost estimates

Allison Portnoy<sup>1</sup>, Emma Clarke-Deelder<sup>2</sup>, Taylor A. Holroyd<sup>3</sup>,  
Tewodaj Mengistu<sup>3</sup>

<sup>1</sup>Department of Global Health, Boston University School of Public Health; <sup>2</sup>Department of Epidemiology and Public Health, Swiss Tropical & Public Health Institute; <sup>3</sup>Gavi, the Vaccine Alliance

# Background

- The Immunization Agenda 2030 aims to reach all people with immunization services, including ‘zero-dose’ children—children who have not received any routine vaccine
- To plan for the efforts to reach zero-dose children and make informed decisions to improve immunization coverage and equity, decision-makers need to know how much these efforts will cost
- Data on the costs of reaching zero-dose children are currently limited—in the short-term, there is a need for proxy estimates for the costs of delivering vaccines to zero-dose children
  - The costs of mobile outreach delivery efforts could be such a proxy—this strategy aims to reach ‘hard-to-reach’ populations with limited access to health services

# Objective

To approximate **the costs of reaching zero-dose children** with standardized country-level estimates of vaccine delivery unit costs for outreach delivery for low- and middle-income countries (LMICs)

# Data

- **Dependent variable:**

- *Childhood outreach delivery* cost per dose from the Immunization Costing Action Network's Immunization Delivery Cost Catalogue 2024 update

- **Covariates:**

- Country-level predictors, i.e., GDP per capita, reported diphtheria-tetanus-pertussis third dose (DTP3) coverage, under-5 population size, under-5 mortality rate, population density, percentage urban population
- Study-level predictors, i.e., study year, economic or financial cost, routine or campaign delivery, full or incremental costing approach

# Analytic model

- A Bayesian meta-regression approach was used to incorporate country-level and study-level predictors
  - Continuous variables standardized to mean zero and unit standard deviation before model fitting
- In addition to study-level predictors, country-level covariates selected according to the best fit model using minimized Akaike's Information Criterion
- Prediction model specified as a generalized linear regression model (GLM) assuming a Gamma likelihood function for the observed data  $y_i$  where the shape parameter  $\alpha$  described the residual variance

$$y_i \sim \text{Gamma}\left(\alpha, \frac{\alpha}{c_i}\right)$$

# Descriptive results

- 48 study observations representing 19 countries
- Cost per dose range: \$0.07 – \$9.85 in 2023 USD


Variable	Estimates (n)
<b>Income</b>	
• LI	24
• LMI	22
• UMI	2
<b>Cost type</b>	
• Economic	27
• Financial	21
<b>Costing approach</b>	
• Full	21
• Incremental	27
<b>Delivery modality</b>	
• Routine	37
• SIA	11

# Best fit model

$$c_i = \exp(\beta_0 + \beta_1 * Year_i + \beta_2 * Econ_i + \beta_3 * Full_i + \beta_4 * Routine_i + \beta_5 * \log(Pop)_i + \beta_6 * DTP3_i)$$

- While the economic cost indicator, routine delivery modality indicator, and the coefficients on  $\log(Pop)$  and DTP3 were statistically significantly different from zero, the coefficients for other predictor variables were not significant
- The fitted model demonstrated increasing costs as service delivery volume (under-five population) and health system capacity (DTP3 coverage) increased

# Original vs. predicted cost per dose




# Predicted economic costs per dose

- In 2023, population-weighted average economic cost per dose was estimated to be **\$7.91 (95% uncertainty interval \$2.44–20.14)** for the full costs of routine outreach vaccine delivery across 131 LMICs
- By income level:
  - \$2.36 (\$0.74–6.17) for low-income (LI) countries
  - \$9.81 (\$2.92–25.53) for lower middle-income (LMI) countries
  - \$8.40 (\$2.57–21.28) for upper middle-income (UMI) countries
- Assuming these predicted costs as a proxy for reaching zero-dose children, costs of reaching a zero-dose child would be scaled by number of vaccine doses in the vaccine program
  - e.g., if we assume vaccine program requires 13 doses\*, the costs of fully vaccinating a zero-dose child would be equivalent to **\$102.83 (\$31.72–261.82)**
  - UNICEF’s estimated delivery cost to fully vaccinate a child in the first year of life is ~\$37

\* 3 Pentavalent (Diphtheria-Tetanus-Pertussis-Hepatitis *B-Haemophilus influenzae* type b), 3 Oral Polio Vaccine, 3 Pneumococcal Conjugate Vaccine, 3 Rotavirus Vaccine, 1 Measles-Containing Vaccine

# Predicted economic costs per dose by GDP per capita and World Bank income level



# Limitations

- Large heterogeneity exists in the data set, which is only partially explained by regression coefficients
  - Within this uncertainty, there may be real differences between countries or “measurement error”
- We are assuming that the data are an unbiased sample of the true value, but costing studies are inconsistent and samples are not always randomly selected
- Outreach and mobile efforts to reach children already reached by ongoing immunization efforts might not be representative of efforts required to reach zero-dose children, who are not reached by the programs informing this analysis by definition
  - It might be even more costly than the studies informing this analysis, and perhaps the upper bound of \$261.82 is a closer approximation of this cost than the point estimate of \$102.83

# Conclusions

- Reaching zero-dose children is crucial for improving equity, and estimates of the costs of doing so are needed to inform budgeting for immunization programs
- Our study provides estimates produced via meta-regression analyses that can help countries to improve budgeting and planning for implementation of future interventions to reach zero-dose children